These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. Hughes BL, Dutt R, Raker C, Barthelemy M, Rossoll RM, Ramratnam B, Wira CR, Cu-Uvin S. Am J Obstet Gynecol; 2016 Dec 15; 215(6):748.e1-748.e12. PubMed ID: 27393267 [Abstract] [Full Text] [Related]
5. Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection. Murphy K, Keller MJ, Anastos K, Sinclair S, Devlin JC, Shi Q, Hoover DR, Starkman B, McGillick J, Mullis C, Minkoff H, Dominguez-Bello MG, Herold BC. PLoS One; 2019 Dec 15; 14(4):e0216049. PubMed ID: 31026271 [Abstract] [Full Text] [Related]
6. A prospective study of hormonal contraceptive use and cervical shedding of herpes simplex virus in human immunodeficiency virus type 1-seropositive women. McClelland RS, Wang CC, Richardson BA, Corey L, Ashley RL, Mandaliya K, Ndinya-Achola J, Bwayo JJ, Kreiss JK. J Infect Dis; 2002 Jun 15; 185(12):1822-5. PubMed ID: 12085333 [Abstract] [Full Text] [Related]
7. The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition. Thurman A, Chandra N, Schwartz JL, Brache V, Chen BA, Asin S, Rollenhagen C, Herold BC, Fichorova RN, Hillier SL, Weiner DH, Mauck C, Doncel GF. AIDS Res Hum Retroviruses; 2019 Sep 15; 35(9):853-864. PubMed ID: 30997816 [Abstract] [Full Text] [Related]
9. Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women. Thurman AR, Chandra N, Yousefieh N, Zalenskaya I, Kimble T, Asin S, Rollenhagen C, Anderson SM, Herold B, Mesquita PM, Richardson-Harman N, Cunningham T, Schwartz JL, Doncel GF. AIDS Res Hum Retroviruses; 2016 Jun 15; 32(6):547-60. PubMed ID: 26750085 [Abstract] [Full Text] [Related]
12. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, Chen HY, Landay A. Clin Vaccine Immunol; 2007 Sep 15; 14(9):1102-7. PubMed ID: 17671228 [Abstract] [Full Text] [Related]
13. Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, Epstein J, Cohen HW, Keller MJ, Herold BC. Am J Reprod Immunol; 2010 Feb 15; 63(2):110-9. PubMed ID: 20015330 [Abstract] [Full Text] [Related]
14. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. Ghanem KG, Shah N, Klein RS, Mayer KH, Sobel JD, Warren DL, Jamieson DJ, Duerr AC, Rompalo AM, HIV Epidemiology Research Study Group. J Infect Dis; 2005 Feb 01; 191(3):358-66. PubMed ID: 15633094 [Abstract] [Full Text] [Related]
15. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, Mayer K, Wright PF, Kappes JC, Ochsenbauer C, Wira CR. PLoS One; 2010 Jun 29; 5(6):e11366. PubMed ID: 20614007 [Abstract] [Full Text] [Related]
16. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC. J Infect Dis; 2006 Jan 01; 193(1):27-35. PubMed ID: 16323128 [Abstract] [Full Text] [Related]
17. Dysregulation in Genital Tract Soluble Immune Mediators in Postmenopausal Women Is Distinct by HIV Status. Ghosh M, Jais M, Delisle J, Younes N, Benyeogor I, Biswas R, Mohamed H, Daniels J, Wang C, Young M, Kassaye S. AIDS Res Hum Retroviruses; 2019 Mar 01; 35(3):251-259. PubMed ID: 30618272 [Abstract] [Full Text] [Related]
18. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, Overbaugh J. AIDS; 2007 Aug 20; 21(13):1771-7. PubMed ID: 17690576 [Abstract] [Full Text] [Related]
19. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. Mugo NR, Stalter RM, Heffron R, Rees H, Scoville CW, Morrison C, Kourtis AP, Bukusi E, Beksinka M, Philip NM, Beesham I, Deese J, Edward V, Donnell D, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. Clin Infect Dis; 2022 Sep 10; 75(4):586-595. PubMed ID: 34910143 [Abstract] [Full Text] [Related]
20. Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women. Thurman AR, Yousefieh N, Chandra N, Kimble T, Asin S, Rollenhagen C, Anderson SM, Herold BC, Freiermuth JL, Starkman BS, Mesquita PMM, Richardson-Harman N, Cunningham T, Hillier S, Rabe L, Schwartz JL, Doncel GF. AIDS Res Hum Retroviruses; 2017 Aug 10; 33(8):807-819. PubMed ID: 28398069 [Abstract] [Full Text] [Related] Page: [Next] [New Search]